Somatopause: dismetabolic and bone effects.

G. Lombardi, L. Tauchmanova, C. Di Somma, T. Musella, F. Rota, M. C. Savanelli, A. Colao

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The physiological changes that the human body undergoes during aging are similar to those observed in GH deficiency (GHD). Early changes of aging are represented by increased fat mass, increased cardiovascular risk, reduced muscle mass and strength, reduced exercise tolerance, thinned skin, decreased strength and impaired quality of life. These observations led to hypothesize that the elderly could be GH deficient and would benefit from GH treatment. However, the effects of GH treatment in healthy elderly subjects by randomized and controlled studies are less promising than initially hypothesized. The etiopathology of age-related bone loss is multifactorial including menopause, andropause, somatopause and secondary hyperparathyroidism. GH has multiple effects on bone, either direct or mediated by IGF-I, stimulating osteoblast proliferation as well as osteoclast differentiation. Consequently, decline in GH secretion reduces bone turnover that causes osteopenia in young adults, but it has been hypothesized that it could protect against fractures in elderly subjects. The increase of bone remodeling achieved by GH therapy may be helpful in elderly men and women who have severely decreased bone turnover and impaired osteoblastic function. In conclusion, the endocrine pattern of aging is distinct from the decrease of GH/IGF-I levels associated with hypopituitarism. However, GH plays a role in metabolism and bone physiology throughout the human life span, although there is insufficient evidence for a clear therapeutic role of rhGH in aging. Thus, more data are needed to define the effects of somatopause to identify who could potentially benefit from the effects of somatotropic treatment.

Original languageEnglish
Pages (from-to)36-42
Number of pages7
JournalJournal of Endocrinological Investigation
Volume28
Issue number10 Suppl
Publication statusPublished - 2005

Fingerprint

Bone Remodeling
Bone and Bones
Insulin-Like Growth Factor I
Andropause
Therapeutics
Hypopituitarism
Secondary Hyperparathyroidism
Exercise Tolerance
Metabolic Bone Diseases
Muscle Strength
Osteoclasts
Menopause
Osteoblasts
Human Body
Osteoporosis
Young Adult
Healthy Volunteers
Fats
Quality of Life
Skin

ASJC Scopus subject areas

  • Endocrinology

Cite this

Lombardi, G., Tauchmanova, L., Di Somma, C., Musella, T., Rota, F., Savanelli, M. C., & Colao, A. (2005). Somatopause: dismetabolic and bone effects. Journal of Endocrinological Investigation, 28(10 Suppl), 36-42.

Somatopause : dismetabolic and bone effects. / Lombardi, G.; Tauchmanova, L.; Di Somma, C.; Musella, T.; Rota, F.; Savanelli, M. C.; Colao, A.

In: Journal of Endocrinological Investigation, Vol. 28, No. 10 Suppl, 2005, p. 36-42.

Research output: Contribution to journalArticle

Lombardi, G, Tauchmanova, L, Di Somma, C, Musella, T, Rota, F, Savanelli, MC & Colao, A 2005, 'Somatopause: dismetabolic and bone effects.', Journal of Endocrinological Investigation, vol. 28, no. 10 Suppl, pp. 36-42.
Lombardi G, Tauchmanova L, Di Somma C, Musella T, Rota F, Savanelli MC et al. Somatopause: dismetabolic and bone effects. Journal of Endocrinological Investigation. 2005;28(10 Suppl):36-42.
Lombardi, G. ; Tauchmanova, L. ; Di Somma, C. ; Musella, T. ; Rota, F. ; Savanelli, M. C. ; Colao, A. / Somatopause : dismetabolic and bone effects. In: Journal of Endocrinological Investigation. 2005 ; Vol. 28, No. 10 Suppl. pp. 36-42.
@article{f5d7c54eac054f2cb50e7f09d4f760cd,
title = "Somatopause: dismetabolic and bone effects.",
abstract = "The physiological changes that the human body undergoes during aging are similar to those observed in GH deficiency (GHD). Early changes of aging are represented by increased fat mass, increased cardiovascular risk, reduced muscle mass and strength, reduced exercise tolerance, thinned skin, decreased strength and impaired quality of life. These observations led to hypothesize that the elderly could be GH deficient and would benefit from GH treatment. However, the effects of GH treatment in healthy elderly subjects by randomized and controlled studies are less promising than initially hypothesized. The etiopathology of age-related bone loss is multifactorial including menopause, andropause, somatopause and secondary hyperparathyroidism. GH has multiple effects on bone, either direct or mediated by IGF-I, stimulating osteoblast proliferation as well as osteoclast differentiation. Consequently, decline in GH secretion reduces bone turnover that causes osteopenia in young adults, but it has been hypothesized that it could protect against fractures in elderly subjects. The increase of bone remodeling achieved by GH therapy may be helpful in elderly men and women who have severely decreased bone turnover and impaired osteoblastic function. In conclusion, the endocrine pattern of aging is distinct from the decrease of GH/IGF-I levels associated with hypopituitarism. However, GH plays a role in metabolism and bone physiology throughout the human life span, although there is insufficient evidence for a clear therapeutic role of rhGH in aging. Thus, more data are needed to define the effects of somatopause to identify who could potentially benefit from the effects of somatotropic treatment.",
author = "G. Lombardi and L. Tauchmanova and {Di Somma}, C. and T. Musella and F. Rota and Savanelli, {M. C.} and A. Colao",
year = "2005",
language = "English",
volume = "28",
pages = "36--42",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "10 Suppl",

}

TY - JOUR

T1 - Somatopause

T2 - dismetabolic and bone effects.

AU - Lombardi, G.

AU - Tauchmanova, L.

AU - Di Somma, C.

AU - Musella, T.

AU - Rota, F.

AU - Savanelli, M. C.

AU - Colao, A.

PY - 2005

Y1 - 2005

N2 - The physiological changes that the human body undergoes during aging are similar to those observed in GH deficiency (GHD). Early changes of aging are represented by increased fat mass, increased cardiovascular risk, reduced muscle mass and strength, reduced exercise tolerance, thinned skin, decreased strength and impaired quality of life. These observations led to hypothesize that the elderly could be GH deficient and would benefit from GH treatment. However, the effects of GH treatment in healthy elderly subjects by randomized and controlled studies are less promising than initially hypothesized. The etiopathology of age-related bone loss is multifactorial including menopause, andropause, somatopause and secondary hyperparathyroidism. GH has multiple effects on bone, either direct or mediated by IGF-I, stimulating osteoblast proliferation as well as osteoclast differentiation. Consequently, decline in GH secretion reduces bone turnover that causes osteopenia in young adults, but it has been hypothesized that it could protect against fractures in elderly subjects. The increase of bone remodeling achieved by GH therapy may be helpful in elderly men and women who have severely decreased bone turnover and impaired osteoblastic function. In conclusion, the endocrine pattern of aging is distinct from the decrease of GH/IGF-I levels associated with hypopituitarism. However, GH plays a role in metabolism and bone physiology throughout the human life span, although there is insufficient evidence for a clear therapeutic role of rhGH in aging. Thus, more data are needed to define the effects of somatopause to identify who could potentially benefit from the effects of somatotropic treatment.

AB - The physiological changes that the human body undergoes during aging are similar to those observed in GH deficiency (GHD). Early changes of aging are represented by increased fat mass, increased cardiovascular risk, reduced muscle mass and strength, reduced exercise tolerance, thinned skin, decreased strength and impaired quality of life. These observations led to hypothesize that the elderly could be GH deficient and would benefit from GH treatment. However, the effects of GH treatment in healthy elderly subjects by randomized and controlled studies are less promising than initially hypothesized. The etiopathology of age-related bone loss is multifactorial including menopause, andropause, somatopause and secondary hyperparathyroidism. GH has multiple effects on bone, either direct or mediated by IGF-I, stimulating osteoblast proliferation as well as osteoclast differentiation. Consequently, decline in GH secretion reduces bone turnover that causes osteopenia in young adults, but it has been hypothesized that it could protect against fractures in elderly subjects. The increase of bone remodeling achieved by GH therapy may be helpful in elderly men and women who have severely decreased bone turnover and impaired osteoblastic function. In conclusion, the endocrine pattern of aging is distinct from the decrease of GH/IGF-I levels associated with hypopituitarism. However, GH plays a role in metabolism and bone physiology throughout the human life span, although there is insufficient evidence for a clear therapeutic role of rhGH in aging. Thus, more data are needed to define the effects of somatopause to identify who could potentially benefit from the effects of somatotropic treatment.

UR - http://www.scopus.com/inward/record.url?scp=33645813121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645813121&partnerID=8YFLogxK

M3 - Article

C2 - 16550721

AN - SCOPUS:33645813121

VL - 28

SP - 36

EP - 42

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 10 Suppl

ER -